Country
Netherlands
A company with technology for microRNA compounds has raised €18.5 million in a Series B financing round to advance a product for patients with advanced solid tumours. The company, InteRNA Technologies, is based in the Netherlands.
Full text available to subscribers only. Click here for information on subscribing to MedNous.